Last reviewed · How we verify
Trivalent influenza vaccine A
Trivalent influenza vaccine A is a Inactivated influenza vaccine Biologic drug developed by Shanghai Institute Of Biological Products. It is currently in Phase 3 development for Seasonal influenza prevention in adults and children.
A trivalent inactivated influenza vaccine that stimulates the immune system to produce antibodies against three strains of influenza virus (typically two A strains and one B strain).
A trivalent inactivated influenza vaccine that stimulates the immune system to produce antibodies against three strains of influenza virus (typically two A strains and one B strain). Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | Trivalent influenza vaccine A |
|---|---|
| Sponsor | Shanghai Institute Of Biological Products |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated viral antigens from three influenza virus strains, which are presented to the immune system to generate humoral and cellular immune responses. This priming allows the vaccinated individual to mount a rapid and effective antibody response upon exposure to circulating influenza viruses, reducing infection risk and disease severity.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site pain, redness, or swelling
- Myalgia
- Headache
- Fever
- Fatigue
Key clinical trials
- Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines (PHASE4)
- Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine (PHASE1, PHASE2)
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (PHASE3)
- Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe
- A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age. (PHASE1)
- Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (PHASE2)
- Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age (PHASE3)
- High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trivalent influenza vaccine A CI brief — competitive landscape report
- Trivalent influenza vaccine A updates RSS · CI watch RSS
- Shanghai Institute Of Biological Products portfolio CI
Frequently asked questions about Trivalent influenza vaccine A
What is Trivalent influenza vaccine A?
How does Trivalent influenza vaccine A work?
What is Trivalent influenza vaccine A used for?
Who makes Trivalent influenza vaccine A?
What drug class is Trivalent influenza vaccine A in?
What development phase is Trivalent influenza vaccine A in?
What are the side effects of Trivalent influenza vaccine A?
Related
- Drug class: All Inactivated influenza vaccine drugs
- Manufacturer: Shanghai Institute Of Biological Products — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Seasonal influenza prevention in adults and children
- Compare: Trivalent influenza vaccine A vs similar drugs
- Pricing: Trivalent influenza vaccine A cost, discount & access